Q32 Bio Inc. (Nasdaq: QTTB) announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata on July 13, 2026.

The company will host a conference call and webcast at 8:00 a.m. ET on that date to discuss the results.

Bempikibart, also known as ADX-914, is a fully human anti-IL-7Rα antibody being evaluated for the treatment of alopecia areata. According to the National Alopecia Areata Foundation, approximately 700,000 people in the United States live with the condition.